Stocktoria
IOVANCE BIOTHERAPEUTICS, INC. IOVA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2008-06-20
IOVANCE BIOTHERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | — | — |
| R&D expense | $300.3M | $276.2M | $333.2M | $294.8M | $259.0M |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M | -$342.7M |
| Income tax | -$2.1M | -$2.8M | -$3.5M | $0 | $0 |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M | -$342.3M |
| EPS (diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| Operating cash flow | -$302.4M | -$353.0M | -$361.8M | -$292.8M | -$227.9M |
| Free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M | -$265.5M |
| Cash & equivalents | $163.1M | $115.7M | $114.9M | $231.7M | $78.2M |
| Inventory | $51.7M | $51.5M | $10.4M | — | — |
| Total assets | $913.2M | $910.4M | $780.4M | $664.0M | $777.3M |
| Total liabilities | $214.6M | $200.0M | $195.7M | $164.3M | $155.7M |
| Shareholders' equity | $698.6M | $710.4M | $584.6M | $499.6M | $621.7M |
Source: SEC EDGAR filings · CIK 0001425205 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.